MCID: CRB037
MIFTS: 66

Cerebral Palsy malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Cerebral Palsy

Aliases & Descriptions for Cerebral Palsy:

Name: Cerebral Palsy 38 12 50 51 29 52 41 3 14 69
Infantile Cerebral Palsy 12 69
Cerebral Palsy, Mixed 69
Mixed Cerebral Palsy 50

Classifications:



External Ids:

Disease Ontology 12 DOID:1969
ICD10 33 G80 G80.9
ICD9CM 35 343.8
MeSH 42 D002547
NCIt 47 C34460

Summaries for Cerebral Palsy

NINDS : 51 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance.CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to mixed cerebral palsy and hereditary spastic paraplegia, and has symptoms including athetosis, back pain and dystonia. An important gene associated with Cerebral Palsy is KANK1 (KN Motif And Ankyrin Repeat Domains 1), and among its related pathways/superpathways are Clathrin derived vesicle budding and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Dexmedetomidine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are homeostasis/metabolism and nervous system

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 50 cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. cerebral palsy is caused by abnormal brain development or damage to the developing brain. most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. there is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. this may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility. last updated: 11/18/2015

MedlinePlus : 41 cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. the disorders appear in the first few years of life. usually they do not get worse over time. people with cerebral palsy may have difficulty walking. they may also have trouble with tasks such as writing or using scissors. some have other medical conditions, including seizure disorders or mental impairment. cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. early signs of cerebral palsy usually appear before 3 years of age. babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. some babies are born with cerebral palsy; others get it after they are born. there is no cure for cerebral palsy, but treatment can improve the lives of those who have it. treatment includes medicines, braces, and physical, occupational and speech therapy. nih: national institute of neurological disorders and stroke

Wikipedia : 71 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 301)
id Related Disease Score Top Affiliating Genes
1 mixed cerebral palsy 33.7 F5 GAD1 PLP1
2 hereditary spastic paraplegia 32.1 F2 IL6 MBL2 TNF
3 neuropathy 29.4 IL1B IL6 TNF
4 pyelonephritis 29.3 F2 IL1B TNF
5 spondylolysis 29.3 IL1B IL6 TNF
6 cerebral palsy, ataxic, autosomal recessive 12.5
7 spastic cerebral palsy 12.4
8 dyskinetic cerebral palsy 12.4
9 spastic diplegia cerebral palsy 12.4
10 cerebral palsy, spastic quadriplegic, 1 12.3
11 cerebral palsy athetoid 12.2
12 cerebral palsy, spastic quadriplegic, 2 12.2
13 spastic hemiplegia 12.1
14 spastic quadriplegia 12.1
15 spastic diplegia 12.1
16 spastic monoplegia 11.7
17 spastic paraplegia 50, autosomal recessive 11.6
18 spasticity 11.4
19 periventricular leukomalacia 11.4
20 foot drop 11.3
21 swallowing disorders 11.3
22 athetosis 11.2
23 hypertonia 11.1
24 dysphagia 11.1
25 developmental coordination disorder 11.1
26 hypotonia 11.1
27 neonatal stroke 11.1
28 kernicterus 11.1
29 infantile hypotonia 11.1
30 inherited congenital spastic tetraplegia 11.1
31 cerebritis 11.1
32 spastic paraplegia 47, autosomal recessive 11.0
33 spastic paraplegia 52, autosomal recessive 11.0
34 intellectual disability - athetosis - microphthalmia 11.0
35 suprabulbar paresis, congenital 10.9
36 spastic paraplegia 51, autosomal recessive 10.8
37 spastic paraplegia 52 10.8
38 hereditary spastic paraplegia 51 10.8
39 primary aldosteronism, seizures, and neurologic abnormalities 10.8
40 congenital laryngeal palsy 10.8
41 parkinsonism-dystonia, infantile 10.8
42 mental retardation, autosomal dominant 26 10.8
43 floppy infant syndrome 10.8
44 hemiplegia 10.6
45 quadriplegia 10.6
46 paraplegia 10.5
47 adenosarcoma of the corpus uteri 10.4 ADD3 GAD1 KANK1
48 multiple familial trichoepithelioma 10.3 F5 MTHFR
49 hereditary spastic paraplegia 75 10.3 AP4B1 AP4S1
50 absence of innominate vein 10.3 F5 MTHFR

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:


athetosis, back pain, dystonia, headache, muscle rigidity, pain, sciatica, seizures, syncope, torticollis, tremor, chronic pain, muscle fibrillation, asterixis, abnormality of extrapyramidal motor function, abnormal head movements, vertigo/dizziness, myokymia, sleeplessness

MGI Mouse Phenotypes related to Cerebral Palsy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.93 AP4E1 AP4M1 APOE F2 F5 GAD1
2 nervous system MP:0003631 9.7 AP4B1 AP4E1 APOE F2 F5 GAD1
3 skeleton MP:0005390 9.28 APOE F2 GAD1 IL1B IL6 MTHFR

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-84-3 187
4
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
5
Levodopa Approved Phase 4,Phase 2 59-92-7 6047
6
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
7
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
8
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
9
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
10
Pyrimethamine Approved, Vet_approved Phase 4 58-14-0 4993
11
Sulfadiazine Approved, Vet_approved Phase 4 68-35-9 5215
12
Sulfamethoxazole Approved Phase 4 723-46-6 5329
13
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
14
Prilocaine Approved Phase 4 721-50-6 4906
15
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
16
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 4 24280-93-1 446541
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
22
Inulin Approved, Nutraceutical Phase 4 9005-80-5 24763
23 Adrenergic Agents Phase 4,Phase 2,Phase 1
24 Adrenergic Agonists Phase 4,Phase 1
25 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
26 Adrenergic alpha-Agonists Phase 4,Phase 1
27 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
28 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
29 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
30 Anesthetics, General Phase 4
31 Anesthetics, Inhalation Phase 4
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
33 Hypnotics and Sedatives Phase 4
34 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Platelet Aggregation Inhibitors Phase 4,Phase 3
37 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1
38 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1
39 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Carbidopa, levodopa drug combination Phase 4
43 Dihydroxyphenylalanine Phase 4,Phase 2,Early Phase 1
44 Dopamine Agents Phase 4,Phase 2,Phase 1
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
46 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
47 incobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
48 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
49 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
50 Carbonic Anhydrase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 797)
id Name Status NCT ID Phase
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4
2 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Unknown status NCT01860196 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4
4 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Unknown status NCT01386255 Phase 4
5 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4
6 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4
7 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
8 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4
9 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
10 Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery Unknown status NCT01889498 Phase 4
11 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
12 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4
13 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4
14 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4
15 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4
16 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4
17 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
18 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4
19 Treatment of Cerebral Toxoplasmosis in HIV/AIDS Completed NCT00367081 Phase 4
20 Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Intermediate Cervical Block. Completed NCT01759940 Phase 4
21 Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions Completed NCT01208584 Phase 4
22 Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy Recruiting NCT02391324 Phase 4
23 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4
24 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Recruiting NCT02633241 Phase 4
25 Intrathecal Baclofen (ITB) Delivery Location and Its Effect on Spasticity Recruiting NCT02903823 Phase 4
26 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox) Recruiting NCT02888548 Phase 4
27 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4
28 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Not yet recruiting NCT02462018 Phase 4
29 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Not yet recruiting NCT03117322 Phase 4
30 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
31 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
32 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
33 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
34 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
35 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
36 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3
37 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3
38 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
39 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3
40 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3
41 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3
42 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3
43 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3
44 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
45 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3
46 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3
47 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3
48 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3
49 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3
50 Effects of Mirror Neurons Stimulation on Motor Skill Rehabilitation in Children With Cerebral Palsy Completed NCT01267929 Phase 3

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

id Genetic test Affiliating Genes
1 Cerebral Palsy 29

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

39
Brain, Testes, Bone, Spinal Cord, Heart, Eye, Cortex
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 1456)
id Title Authors Year
1
Bilateral globus pallidus internus deep brain stimulation for dyskinetic cerebral palsy supports success of cochlear implantation in a 5-year old ex-24A week preterm twin with absent cerebellar hemispheres. ( 28017556 )
2017
2
Focusing on Participation: A Commentary on "Current Rehabilitation Practices for Children with Cerebral Palsy: Focus and Gaps". ( 28080172 )
2017
3
Body composition, diet, and physical activity: a longitudinal cohort study in preschoolers with cerebral palsy. ( 28077375 )
2017
4
Biofeedback interventions for people with cerebral palsy: a systematic review protocol. ( 28086958 )
2017
5
Standing activity intervention and motor function in a young child with cerebral palsy: A case report. ( 28071965 )
2017
6
Stability of the Gross Motor Function Classification System in children and adolescents with cerebral palsy: a retrospective cohort registry study. ( 28083887 )
2017
7
Family adaptation to cerebral palsy in adolescents: A European multicenter study. ( 28087202 )
2017
8
Reliability and sources of variation of the ABILHAND-Kids questionnaire in children with cerebral palsy. ( 28068864 )
2017
9
Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy. ( 27732905 )
2017
10
Stable cognitive functioning with improved perceptual reasoning in children with dyskinetic cerebral palsy and other secondary dystonias after deep brain stimulation. ( 27836441 )
2017
11
Plantar flexor muscle weakness and fatigue in spastic cerebral palsy patients. ( 28064025 )
2017
12
Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial. ( 28074392 )
2017
13
First words: speech and language interventions in cerebral palsy. ( 28090650 )
2017
14
Results and complications of percutaneous pelvic osteotomy and intertrochanteric varus shortening osteotomy in 54 consecutively operated GMFCS level IV and V cerebral palsy patients. ( 28083677 )
2017
15
Statistical Parametric Mapping to Identify Differences between Consensus-Based Joint Patterns during Gait in Children with Cerebral Palsy. ( 28081229 )
2017
16
Hyperbaric oxygen therapy is safe and effective for the treatment of sleep disorders in children with cerebral palsy. ( 28079475 )
2017
17
Changes in Cardiorespiratory Responses and Kinematics With Hippotherapy in Youth With and Without Cerebral Palsy. ( 28075704 )
2017
18
Structured skill practice during intensive bimanual training leads to better trunk and arm control than unstructured practice in children with unilateral spastic cerebral palsy. ( 27912104 )
2017
19
Three-dimensional lumbar segment movement characteristics during paediatric cerebral palsy gait. ( 28088678 )
2017
20
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population. ( 28081025 )
2017
21
Gross motor function in children with spastic Cerebral Palsy and Cerebral Visual Impairment: A comparison between outcomes of the original and the Cerebral Visual Impairment adapted Gross Motor Function Measure-88 (GMFM-88-CVI). ( 27771178 )
2017
22
WAKE-up exoskeleton to assist children with Cerebral Palsy: design and preliminary evaluation in level walking. ( 28092566 )
2017
23
A systematic review of scales to measure dystonia and choreoathetosis in children with dyskinetic cerebral palsy. ( 28485494 )
2017
24
Can parents provide hand function training for their child with cerebral palsy? ( 28083905 )
2017
25
Addressing heterogeneous needs using cerebral palsy registers. ( 28070888 )
2017
26
Six-Minute Walk Test in Children With Spastic Cerebral Palsy and Children Developing Typically. ( 26808959 )
2016
27
Effects of Abnormal Oral Reflexes on Speech Articulation in Persian Speaking Children with Spastic Cerebral Palsy. ( 27375753 )
2016
28
Should mirror movements modify therapeutic strategies for unilateral spastic cerebral palsy? ( 27521274 )
2016
29
Change in Pulmonary Function after Incentive Spirometer Exercise in Children with Spastic Cerebral Palsy: A Randomized Controlled Study. ( 26996580 )
2016
30
Effects of severity of gross motor disability on anticipatory postural adjustments while standing in individuals with bilateral spastic cerebral palsy. ( 27399205 )
2016
31
Gastrocnemius muscle-tendon interaction during walking in typically-developing adults and children, and in children with spastic cerebral palsy. ( 27545082 )
2016
32
Prospective Randomized Study of Oral Diazepam and Baclofen on Spasticity in Cerebral Palsy. ( 27504360 )
2016
33
Reliability and Responsiveness of the Timed Up and Go Test in Children With Cerebral Palsy. ( 27661230 )
2016
34
Mechanical and material properties of the plantarflexor muscles and Achilles tendon in children with spastic cerebral palsy and typically developing children. ( 27515440 )
2016
35
An individual approach for optimizing ankle-foot orthoses to improve mobility in children with spastic cerebral palsy walking with excessive knee flexion. ( 27131186 )
2016
36
Adding parent-delivered therapy does not improve upper limb function more than repeated practice alone in children with cerebral palsy [commentary]. ( 27634167 )
2016
37
The effect of postural control and balance on femoral anteversion in children with spastic cerebral palsy. ( 27390397 )
2016
38
Improving functional outcomes for children with unilateral cerebral palsy: the quest for the right intervention. ( 27634212 )
2016
39
The clinical outcomes of deep gray matter injury in children with cerebral palsy in relation with brain magnetic resonance imaging. ( 27214680 )
2016
40
Estimation of the number of children with cerebral palsy using nationwide health insurance claims data in Japan. ( 27644438 )
2016
41
Reflections on the Functional Communication Classification System for children with cerebral palsy. ( 27169381 )
2016
42
Safety profile of incobotulinum toxin A [Xeomin(Ar)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. ( 27177451 )
2016
43
Correlation between the Gait Deviation Index and gross motor function (GMFCS level) in children with cerebral palsy. ( 27177476 )
2016
44
Longitudinal development of hand function in children with unilateral spastic cerebral palsy aged 18 months to 12 years. ( 27017925 )
2016
45
Pathogenesis of cerebral palsy through the prism of immune regulation of nervous tissue homeostasis: literature review. ( 27638717 )
2016
46
Effects of a Nintendo Wii exercise program on spasticity and static standing balance in spastic cerebral palsy. ( 27538127 )
2016
47
Effect of r-TMS over standard therapy in decreasing muscle tone of spastic cerebral palsy patients. ( 27010377 )
2016
48
Serum Leptin as a Nutritional Biomarker in Children with Cerebral Palsy. ( 27265160 )
2016
49
Effect of Transcranial Direct Current Stimulation Combined With Virtual Reality Training on Balance in Children With Cerebral Palsy: A Randomized, Controlled, Double-Blind, Clinical Trial. ( 27644454 )
2016
50
Contractile behavior of the medial gastrocnemius in children with bilateral spastic cerebral palsy during forward, uphill and backward-downhill gait. ( 27208665 )
2016

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh37 Chromosome 10, 111882007: 111882007

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

GO Terms for Cerebral Palsy

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 clathrin-coated pit GO:0005905 9.33 AP4B1 AP4E1 AP4S1
2 trans-Golgi network membrane GO:0032588 9.26 AP4B1 AP4E1 AP4M1 AP4S1
3 endosome lumen GO:0031904 8.92 AP4B1 AP4E1 AP4M1 AP4S1

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.84 APOE F2 F5 IL6
2 defense response to Gram-positive bacterium GO:0050830 9.7 IL6 MBL2 TNF
3 positive regulation of interleukin-6 production GO:0032755 9.58 IL1B IL6 TNF
4 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.57 IL1B TNF
5 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.56 IL1B TNF
6 positive regulation of chemokine biosynthetic process GO:0045080 9.55 IL1B TNF
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.54 IL1B IL6 TNF
8 negative regulation of lipid storage GO:0010888 9.51 IL6 TNF
9 negative regulation of platelet activation GO:0010544 9.49 APOE F2
10 regulation of establishment of endothelial barrier GO:1903140 9.48 IL1B TNF
11 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.46 IL6 TNF
12 positive regulation of fever generation GO:0031622 9.43 IL1B TNF
13 acute-phase response GO:0006953 9.43 F2 IL6 MBL2
14 sequestering of triglyceride GO:0030730 9.32 IL1B TNF
15 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.16 IL1B TNF
16 positive regulation of phagocytosis GO:0050766 9.13 IL1B MBL2 TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 8.8 APOE IL1B TNF

Sources for Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....